Review Article

Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It

Aswar Urmila, Patil Rashmi, Ghag Nilam, and Bodhankar Subhash

Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be University), Erandwane, Pune 411038, India

Correspondence should be addressed to Aswar Urmila; urmila.aswar@bharatividyapeeth.edu

Received 17 June 2021; Revised 14 October 2021; Accepted 23 October 2021; Published 30 November 2021

Academic Editor: Xiaomu Li

Copyright © 2021 Aswar Urmila et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The RAS (renin-angiotensin system) is the part of the endocrine system that plays a prime role in the control of essential hypertension. Since the discovery of brain RAS in the seventies, continuous efforts have been put by the scientific committee to explore it more. The brain has shown the presence of various components of brain RAS such as angiotensinogen (AGT), converting enzymes, angiotensin (Ang), and specific receptors (ATR). AGT acts as the precursor molecule for Ang peptides—I, II, III, and IV—while the enzymes such as prorenin, ACE, and aminopeptidases A and N synthesize it. AT1, AT2, AT4, and mitochondrial assembly receptor (MasR) are found to be plentiful in the brain. The brain RAS system exhibits pleiotropic properties such as neuroprotection and cognition along with regulation of blood pressure, CVS homeostasis, thirst and salt appetite, stress, depression, alcohol addiction, and pain modulation. The molecules acting through RAS predominantly ARBs and ACEI are found to be effective in various ongoing and completed clinical trials related to cognition, memory, Alzheimer’s disease (AD), and pain. The review summarizes the recent advances in the brain RAS system highlighting its significance in pathophysiology and treatment of the central nervous system-related disorders.

1. Introduction

The renin-angiotensin system (RAS) is of paramount importance, having a role in the regulatory pathway involved in the maintenance of blood pressure (BP), body fluid volume, and sodium homeostasis. Conventional RAS involves the conversion of inactive angiotensinogen into angiotensin I (Ang I) in the presence of renin which is released from the kidney in response to low blood volume. Angiotensin-converting enzyme (ACE) converts Ang I into angiotensin II (Ang II) which acts on an angiotensin type 1 (AT1) and angiotensin type 2 (AT2) receptor. AT1 and AT2 are involved in various physiological changes such as an increase in BP, volume overload, and facilitation of aldosterone release. Intrinsic brain RAS is an enzyme-neuropeptide system having functional components (angiotensinogen, peptidases, angiotensin, and specific receptor proteins) with important biological and neurobiological activities in the brain.

2. History of Brain RAS

Renin was first named as a kidney hormone by Tigerstedt and Bergman in the year 1898, where they observed its pressure effects in rabbits [1]. Angiotensin was discovered during the late 1930s concurrently by Page in the United States and by Braun-Menenez and his colleagues in South America [2]. Ganten et al. in 1970 proposed that even after nephrectomy of adult mongrel dogs, the tissue renin activity persisted even after 12 days [3]. As plasma renin is unable to cross the blood-brain barrier, it was predicted that there is the existence of brain RAS independent of the kidney.

Philips and Felix [4] proved the presence of Ang II-activated neurons in the brain and subfornical organs [4]. The results indicated that the components of the renin/angiotensin system are available at the level of the brain cell itself. All the components of brain RAS such as enzyme iso-renin, ANG, Ang I, converting enzymes, and Ang II are found in the brain [5–9]. Brain RAS and circulating RAS
have been proven to be independent of each other [10–12]. Glial cells are identified as the site of synthesis of AGT [13]. These RAS peptides are present in astrocytes, glial cells, oligodendrocytes, and neurons of various areas of the brain [14, 15] such as the basal ganglia, cerebral cortex, and hippocampus [16]. The review explains the recent advances in the brain RAS system. It also highlights the status of the agonist and antagonist of brain RAS in the treatment of various neurological disorders.

2.1. Angiotensinogen. AGT is a high molecular weight molecule (49.548), made up of 453 amino acids (aa) synthesized in the liver. It is similar to α1 antitrypsin and is affiliated to the Serpin gene family [17]. It is present centrally in the brain with about 90% being expressed in astroglial cells and in some neurons present in regions of the brain controlling cardiovascular and other metabolic functions [18, 19]. However, renin is endogenously expressed in the brain, and increased brain RAS activity is also reported for inducing moderate hypertension; certain experimental evidence also suggests that AGT expression in the brain and circulating AGT regulation is an independent phenomenon [20]. For example, ACE blockade for a long time causes the lowering of AGT levels in plasma, but not in cerebrospinal fluid (CSF). It is suggested that Ang I is not formed in the brain, and availability of Ang II might be because of its excess from periphery to the brain, as it itself is BBB destructive [21]. ACE inhibits the production of Ang II and alone cannot contribute to Ang II levels in the CSF leading to the increase in BP [22]. The ACE inhibitor captopril when administered centrally normalizes BP and renal sympathetic nerve activity hence improving brain RAS function [34]. ACE2, a form of ACE, was first identified in the year 2000 [35, 36]. The human ACE2 (hACE2) protein is a zinc metalloproteinase with 805 amino acids. ACE2 cleaves the COOH-terminal residue of the decapptide. Ang I thus generates Ang (1-9) which is subsequently converted into Ang (1-7) [36, 37]. It shows a greater affinity for Ang II in comparison with Ang I. ACE2 has an important role in counterregulating the actions of the well-documented ACE/Ang II/AT1R axis which has a vasoconstrictive effect. ACE2 cleaves Ang II to Ang (1-7) which promotes vasodilation and has beneficial effects on cardiovascular diseases [38, 39]. Injection of Ang (1-7) into the brain resulted in a fall in arterial blood pressure indicating the central role of Ang (1-7) to counteract the rise in BP by Ang II. Thus, imbalance between ACE and ACE2 would affect blood pressure [40]. Local inhibition of brain ACE2 induces a reduction in baroreflex sensitivity. ACE2 is also the functional receptor for coronavirus associated with the acute respiratory syndrome, i.e., SARS-CoV [38].

2.2. Ang III and Ang IV. Ang II in the presence of aminopeptidase A (APA) gets converted into Ang III, which is abundantly found in the brain [24]. Ang III is further converted into Ang IV by aminopeptidase N (APN) and aminopeptidase B (APB). Ang III acts through the AT2 receptor and has a main role in the regulation of BP and homeostasis [25]. Ang IV has the ability to bind to the AT1 and AT4 receptors. Ang IV when bound to the AT1 receptor showed the vasoconstrictor effect, and with the AT4 receptor, it improved learning and memory response [26]. Cognition enhancement is mainly because of its ability to increase cholinergic neurotransmission in the hippocampal region [27]. APA inhibitors, amastatin and RB150 (orally active), inhibit the conversion of Ang II to III in the brain thereby increasing Ang II which decreases BP and reduces the pressor response [28] via the AT2 receptor. The preclinical safety and efficacy of RB150 have taken it to a phase I study, where it (RB150/QGC001) was found to be clinically and biologically well-tolerated in healthy volunteers after single oral administrations up to 2000 mg. Thus, APA inhibitors open a new avenue as an oral antihypertensive drug segment.

In contrast, when APN (inhibiting metabolism of Ang III) was blocked by intracerebroventricular (icv) injection of PC18 (2-amino-4-methylsulfonyl butane thiol), this resulted in rise in BP due to a central mechanism of Ang III. This effect was blocked by the AT1 antagonist losartan suggesting involvement of the AT1 receptor in producing the pressor response by Ang III [29].

2.3. Converting Enzymes of the Brain RAS: Renin/Prorenin. The active form of renin in the brain is prorenin. It is present in a low concentration called as prorenin. In the brain, it is present within neurons and astrocytes in two forms: intracellular renin and secreted renin (prorenin) [30, 31]. Prorenin acts on a prorenin receptor, activation of which leads to the generation of angiotensin peptides which activate the AT1 receptor resulting in GPCR signaling [32].

2.4. ACE and ACE2. Brain ACE is a key component of the brain RAS and is expressed in many regions of the brain (endothelium of central vasculature, choroid plexus, and astrocytes) especially in the regulation of BP [32]. It is a dipeptidyl peptidase in nature and hydrolyzes bradykinin, tachykinin, or substance P in the brain [33]. ACE cleaves Ang I to the active octapeptide Ang II. Icv infusion of ACE into the brain of Sprague-Dawley rats has shown to increase Ang II levels in the CSF leading to the increase in BP [32]. The ACE inhibitor captopril when administered centrally normalizes BP and renal sympathetic nerve activity hence improving brain RAS function [34]. ACE2, a form of ACE, was first identified in the year 2000 [35, 36]. The human ACE2 (hACE2) protein is a zinc metalloproteinase with 805 amino acids. ACE2 cleaves the COOH-terminal residue of the decapptide. Ang I thus generates Ang (1-9) which is subsequently converted into Ang (1-7) [36, 37]. It shows a greater affinity for Ang II in comparison with Ang I. ACE2 has an important role in counterregulating the actions of the well-documented ACE/Ang II/AT1R axis which has a vasoconstrictive effect. ACE2 cleaves Ang II to Ang (1-7) which promotes vasodilation and has beneficial effects on cardiovascular diseases [38, 39]. Injection of Ang (1-7) into the brain resulted in a fall in arterial blood pressure indicating the central role of Ang (1-7) to counteract the rise in BP by Ang II. Thus, imbalance between ACE and ACE2 would affect blood pressure [40]. Local inhibition of brain ACE2 induces a reduction in baroreflex sensitivity. ACE2 is also the functional receptor for coronavirus associated with the acute respiratory syndrome, i.e., SARS-CoV [38].

2.5. Other Converting Enzymes: Aminopeptidase. As per the literature, renin is present in a very minute concentration in the brain and alone cannot contribute to Ang II generation. Hence, alternative converting enzymes such as tonin, cathepsin G, and chymase are involved which bypass the Ang I step and directly convert AGT to Ang II. Cathepsin G is a serine protease located in the neutrophil leukocytes, red blood cell membranes, and intracellular granules. Renin and cathepsins have a similar structure, which in the absence of renin leads to the generation of Ang II. Tonin is a serine proteinase also called rat kallikrein 2 is present in the astrocytes and thalamus of the brain. In case of absence or limited release of renin in the brain, tonin is responsible for Ang II generation [41]. Another enzyme chymase, which is a serine protease and is released from the mast cell, is also involved in the generation of Ang II. The one derived from humans
has the highest Ang II generation capacity as compared to rat and rabbit chymase [42]. Other cleaving enzymes are aminopeptidases that play a very important role in the regulation of the RAS, and their inhibition shows significant effects (discussed earlier). APA is also known as glutamyl aminopeptidase and hydrolyzes the N-terminal of acidic amino acids. APA converts Ang II to Ang III. APN is alanyl aminopeptidase which hydrolyzes neutral amino acid residues. APB also called arginine aminopeptidase hydrolyzes N-terminal basic amino acids [43].

2.6. Angiotensin Receptors

2.6.1. AT1 Receptors. In brain RAS, four types of angiotensin receptors exist—AT1, AT2, AT4, and MasR. AT1 and AT2 receptors are G protein-coupled receptor kinase having 7 transmembrane subunits and are of prime importance. AT2 is 34% identical at the amino acid level with the AT1 receptor [44].

AT1 receptors are located in the organum vasculosum of the laminae terminalis (OVLT), the suprachiasmatic nucleus (SCN), the preoptic periventricular nucleus (PVN), and the median eminence. It consists of 359 amino acid sequences and has a molecular weight of 40–42 kDa. AT1 has 2 subtypes AT1A and AT1B which have a similar amino acid sequence but different pharmacological properties [45]. AT1A shows typical binding characteristics of the AT1 receptor, and AT1B has a 10000-fold higher affinity for the AT2 receptor antagonist PD123319. Ang II binds to the AT1 receptor by a transmembrane domain with the help of an extracellular loop. Ang II acts through AT1 receptor-Gi- and Gq-coupled mechanisms and causes vasoconstriction, hypertension, increased oxidative stress, and vasopresin release. A Gi protein-coupled mechanism involves inhibition of adenylyl cyclase and stimulation of phospholipase C (PLC). PLC forms Diacylglycerol (DAG) and cyclic AMP [46] (vasodilator in nature); it also releases protein kinase C (PKC) which results in vasoconstriction by the Gi inhibitory mechanism. Gq protein which activates the secondary messenger inositol triphosphate (IP3), and DAG releases phospholipase A2 (PLA2) and PLD, which in turn generate arachidonic acid having a role in inflammation (Figure 1). Icv infusion of the AT1 antagonist losartan inhibits hypertensive response to Ang II [47].

2.6.2. AT2 Receptors. The AT2 receptor predominates in the midbrain mostly in the inferior olive, locus coeruleus, thalamic nuclei, medial amygdala, and molecular layers of the cerebellum. AT2 receptors are divided into two subtypes AT2A and AT2B. AT2A is reported to be present in the ventral thalamic nuclei, medial geniculate nuclei, and locus coeruleus and is sensitive to guanine nucleotides, pertussis toxin, and dithiothreitol. The AT2B subtype is located in the inferior olive and is found to be insensitive to the above-mentioned agents [48]. AT2 receptor activation causes lowering of BP and antihypertensive effect in neurogenic hypertension by the restoration of baroreflex [49].

AT2 receptors are found in the fetus CNS and play an important role in the differentiation and development of CNS. They also contribute to repairing damaged DNA [50]. Ang II activates the AT2 receptor and causes K+ channel activation and inhibits Ca2+ release. It stimulates arachidonic acid release by acting through PLA2 and activates several phosphatases like protein tyrosine phosphatase, MAP kinase phosphatase 1, SH2-domain-containing phosphatase 1 (SHP-1), and serine-threonine phosphatase 2A [51–53]. This molecular-level action causes numerous effects like differentiation, vasodilation, and apoptosis. AT2 receptor activation therefore produces a neuroprotective effect (Figure 2).

2.6.3. AT4 Receptors. AT4 receptors along with cholinergic neurons are present in the brain in the cerebral cortex and hippocampus, which are involved in cognition (memory formation), sensory, and motor performances [54, 55]. It increases cholinergic transmission and improves cognitive improvement abilities [56]. It is an insulin-regulated aminopeptidase (IRAP), and it shows its effect after binding to the ligand. Ang IV shows its pressor response through the AT1 receptor [57]. Ligands binding to AT1 and AT2 receptors do not bind to AT4 receptors proving that AT4 is not a GPCR but a member of the growth factor or cytokine family of receptors. The signal transduction mechanism of the AT4 receptor is still unclear for brain RAS [58].

2.6.4. Mitochondrial Assembly Receptor (MasR). MasR initially known as protooncogene is a G protein-coupled receptor. Mas expression is found in the heart, kidney, lung, liver, spleen, tongue, and skeletal muscle and excessively in the brain [59]. In the brain, they are specifically present in the NTS, RVLM, caudal ventrolateral medulla (CVLM), inferior olive, parvo- and magnocellular portions of the PVN, supraoptic nucleus, and lateral preoptic area [46]. The endogenous activation ligand for MasR is angiotensin (1-7). It is a negative regulator of Ang II-activated AT1R [35, 39]. Hence, the MasR agonist shows similar effects as Ang II receptor antagonists. The discovery of MasR led to the concept of two arms of RAS showing different actions: one comprising classic ACE/Ang II/AT1R (vasoconstrictive, hypertensive, cholinergic, and fibrotic) and the other comprising ACE2/Ang (1-7)/Mas (provasodilatory, antihypertensive, antifibrotic, and antitumor) [60]. The latter one plays an important role in the critical component of pulmonary systems, gastric mucosa, and cancer. Recently, experimental and clinical pieces of evidence suggested that Ang (1-7) or Mas analogs exhibit strong anti-inflammatory responses mediated by SARS-CoV-2 [61, 62]. The details have been discussed in the later part of the review.

2.7. Role of Brain RAS in the Regulation of Various Physiological Activities and the Drugs Acting on It

2.7.1. Regulation of Cardiovascular Function through the Brain. Ang II acts as a neurotransmitter by activating its subtypes in different regions of the brain and thereby regulating neurogenic hypertension by sympathetic activation and baroreflexes. Brain RAS along with the sympathetic nervous system (SNS) and vasopressin release plays a crucial role in managing hypertension [63]. The release of vasopressin occurs from the
hypothalamo-pituitary system while SNS activation occurs by the AT2 receptor via Ang II and Ang III. This leads to stimulation of pressor response and inhibition of baroreflex which causes an increase in the release of AVP into circulation and leads to increased BP. The central role of BP modulation by brain RAS is further confirmed by the fact that APA- and APN-specific inhibitors mainly acting through Ang III production and inhibition of the K+ channel. AT2 receptor stimulation activates several phosphatases like protein tyrosine phosphatase, MAP kinase phosphatase 1 (MKP-1), SH2-domain-containing phosphatase 1 (SHP-1), and serine threonine phosphatase 2A. When this phosphatase gets activated, there is inactivation of extracellular signal-regulated kinase (ERK), which leads to potassium channel opening and inhibition of T-type Ca2+ channels. Abbreviations: PLA: phospholipase A; PLC: phospholipase C; PLD: phospholipase D; IP3: inositol (1;4;5) triphosphate; DAG: diacylglycerol; PKC: protein kinase C; PTP: protein tyrosine phosphatase; PP2A: serine/threonine phosphatase 2A; ERK: extracellular signal-regulated kinase.

Fig. 1: Signal transduction mechanism for angiotensin receptors—AT1 and AT2. Ang II binds to the AT1 receptor and shows vasoconstrictor action through Gi- and Gq-coupled mechanisms. Gi protein-coupled mechanism involves inhibition of adenyl cyclase and phospholipase C stimulation coupled with Gq protein which activates secondary messengers like IP3 and diacylglycerol. Ca2+ released from the above pathway causes vasoconstriction. Vasoconstriction is also caused by protein kinase C from diacylglycerol and cAMP (vasodilator in nature) from the adenyl cyclase inhibitory pathway. Gq-coupled mechanism activates phospholipase A2 and D, causing generation of arachidonic acid. Ang II binds with the AT2 receptor and by negative coupling with guanylyl cyclase shows Ca2+ inhibition and activation of the K+ channel. Also, the AT2 receptor acts through phospholipase A2 and stimulates arachidonic acid release. AT2 receptor stimulation activates several phosphatases like protein tyrosine phosphatase, MAP kinase phosphatase 1 (MKP-1), SH2-domain-containing phosphatase 1 (SHP-1), and serine threonine phosphatase 2A. When this phosphatase gets activated, there is inactivation of extracellular signal-regulated kinase (ERK), which leads to potassium channel opening and inhibition of T-type Ca2+ channels. Abbreviations: PLA: phospholipase A; PLC: phospholipase C; PLD: phospholipase D; IP3: inositol (1;4;5) triphosphate; DAG: diacylglycerol; PKC: protein kinase C; PTP: protein tyrosine phosphatase; PP2A: serine/threonine phosphatase 2A; ERK: extracellular signal-regulated kinase.

2.8. Role of Brain RAS in Thirst, Sodium Uptake, and Vasopressin Release

2.8.1. Modulation of Thirst. Brain RAS influences BP by modulating synaptic nerve activity and stimulates behavioral changes that result in salt intake and initiation of thirst. Dehydration can be classified into extracellular (i.e., volumetric) or intracellular (i.e., osmotic). Brain structures involved in drinking behavior are the lamina terminalis and anteroventral third cerebral ventricle region (AV3V) including the SFO, OVLT, MnPO, and periventricular preoptic nuclei (PePO) which show high AT1 mRNA expression and high density

Inhibiting brain RAS by AT1 blockade in the brain leads to a decrease in blood pressure. However, there is need of preclinical studies where an angiotensin inhibitor like cardioprotector is required.
of AT1 binding sites [25]. Volumetric dehydration caused by hemorrhage results in a decrease in blood volume and leads to baro/volume receptors in the kidney for renin release. It results in the start of a cascade of events that produce Ang II which plays an important role in the initiation of thirst [64].

When angiotensin reaches its threshold level (500 pg/ml by 48 h of dehydration), it penetrates the capillaries of SFO and OVLT. AT1 receptor expression causes activation of detectors in the arch of the aorta, carotid sinus, and great veins that send signals to the brain. It stimulates the thirst center in the brain to initiates a search for water, and antidiuretic hormone (ADH) is released. It results in decreased urine production and increased Na⁺ ingestion (sodium appetite). Extracellular dehydration thus increases thirst and sodium appetite.

2.8.2. Sodium Uptake. Aldosterone is the hormone of sodium regulation, which plays an important role in the brain by sensitizing specific areas (hypothalamus and hindbrain) and affects circulating levels of Ang II. It also acts in the kidney via the distal tubule and collecting duct through stimulation of the sodium-potassium ATPase pump. The combined effect of aldosterone in the brain and kidney stimulates sodium appetite by inhibiting sodium excretion via the kidney and increasing thirst [64].

2.8.3. Vasopressin Release. In the case of severe dehydration or hypovolemia, circulating angiotensin stimulates AT1A receptors in SFO and OVLT leading to activation of neuronal outputs from angiotensin neurons to PVN and SON, hence the release of angiotensin. This causes to increase the firing rate of vasopressin neurons and release of AVP from the posterior pituitary into circulation thereby combating fall in BP [65]. Vasopressin is also released when Ang II is injected in the brain and further activates the somatic nervous system and inhibits the baroreceptor reflex [66]. Angiotensin through vasopressin also promotes thermoregulation...
as observed by Ang II-facilitated heat loss in rats due to tail skin vasodilatation and by stimulation of central AVP release. Icv administration of the AT1 antagonist losartan in rats which were preexposed to a hot environment for 1 h showed the inhibition of the thermoregulatory cooling mechanism. It prevents splanchnic nerve activity and reduces the distribution of blood to the skin [65].

2.8.4. Role of Brain RAS in Stroke (Neuroprotection). Brain RAS has a much wider range of neural effects and is involved in Alzheimer’s disease (AD), stroke, memory, learning, alcoholism, and stress [67]. Reduction or interruption of cerebral blood flow results in ischemic stroke. It is followed by neuronal necrosis and brain apoptosis resulting in serious damage to surrounding cells. Ang II stimulates the AT2 receptor and shows stroke-protective effects. Angiotensin receptor blockers (ARBs) show a neuroprotective effect by selectively blocking AT1 receptors leading to a decrease in local vasoconstriction. Further, free Ang II activates more AT2 receptors causing local vasodilatation and decreases local brain blood flow. Icv administration of the AT1 antagonist losartan and shows stroke-protective effects. AT1R or/and activating PPARγ may cause cerebral protection [70] (Figure 2). Telmisartan, ramipril, candesartan, and perindopril have been studied under clinical trials named PROfESS, HOPE, HOPE-3, and PROGRESS, respectively, and found to be significantly effective. The details of the studies are mentioned in Table 1.

2.8.5. Role of Brain RAS in Neuronal Damage. In brain RAS, Ang II plays an important role in neuronal damage, mainly acting through the dopaminergic neurons (nigrostriatal system) and microglial cells (inflammatory cells). It acts through the Ang II-mediated AT1/NOx axis and generates high-level superoxide ROS. Ang II acting through the AT1 receptor activates the NADPH-oxidase complex, which mediates various oxidative stress (OS) and inflammatory processes resulting in tissue damage leading to degenerative diseases [71, 72]. AT1-induced NOx activation is initiated by protein kinase C (PKC) in microglial cells [73]. Administration of ACEI and ARBs blocked the action of Ang II and showed a reduction in neurotoxin-induced levels of protein oxidation and lipid peroxidation and dopaminergic neuron protection [74] (Figure 2).

2.8.6. Parkinson’s Disease (PD). PD is a neurodegenerative, movement disorder that occurs due to the progressive loss of dopaminergic neurons. Brain dopamine receptors are present in the substantia nigra pars compacta (SNPc) and striatum which has also shown the presence of the AT1 receptor [75]. Ang II activates NOx complex-stimulated superoxide generation by inflamed cells causing the death of dopaminergic neurons. ARBs (telmisartan, candesartan, and losartan) and ACEI (captopril, perindopril) are found to be potent against preclinical models of PD, although there are very limited clinical studies available [76–78].

2.8.7. Role of Brain RAS in Memory Facilitation. Ang IV and cholinergic neurons are closely associated with the neocortex and hippocampus, which are involved in cognitive processing. Conversion of Ang II to Ang IV results in a memory-enhancing effect. The Ang IV analog Nle1-AngIV facilitates long-term potentiation (LTP) in learning and memory [79]. Elevated brain Ang II in AD interferes with Ach release from the cortex and affects cognitive functions. AT1R blockade by ARBs (telmisartan, losartan, valsartan, candesartan, and olmesartan) facilitates additional unbound Ang II available for conversion to Ang III and further to Ang IV and facilitates learning and memory. Also, the synthesis of Ang II is decreased by ACEI (perindopril, ramipril) which consequently increases Ach release and also the synthesis of Ang IV. Thus, coadministration of ACEI with AT1 antagonists prevents the formation and action of Ang II and enhances the formation of Ang IV, and it has been proven for its memory-enhancing property [80].

2.8.8. Role of Brain RAS in AD and Dementia. AD is a multifactorial, complex, neurodegenerative disease that leads to dementia characterized by deposits of amyloid β (Aβ) (1–42), hyperphosphorylation of microtubule-associated protein tau, cholinergic neuronal loss, neuroinflammation, and mitochondrial damage [81]. Overexpression of ACE is observed in the hippocampus, frontal cortex, and caudate nucleus in patients with AD. There are contradictory effects observed for ACEIs in the treatment of Alzheimer’s disease (AD) which are discussed below in detail. Some studies claim ACE inhibitors to be detrimental as ACE converts Aβ1–42 to Aβ1–40 (neuroprotective). Other studies have reported ACEI to be beneficial. It improved cerebral blood flow due to inhibition of the formation of Ang II. ACEI is also demonstrated to inhibit the release of inflammatory cytokines thereby attenuating neurodegeneration. ACE inhibition by Icv administration of perindopril has shown to ameliorate neurodegeneration [82, 83]. ARBs, namely, telmisartan, losartan, candesartan, valsartan, olmesartan, and eprosartan, by their inhibitory action on AT1R have shown to attenuate AD condition. They show their effect by the decrease in amyloidosis, microglial activation, reduced neuroinflammation, and improved cerebral blood flow. Candesartan and telmisartan have been studied clinically. A comparative clinical study of lisinopril with that of candesartan in 141 patients under the CALIBREX study demonstrated improved cognitive performance in the candesartan arm than lisinopril. With telmisartan’s virtue of efficacy in preclinical studies under a clinical trial sponsored by the Alzheimer’s Drug Discovery Foundation with 150 patients, the trial is open labelled and comparative with perindopril; it is expected to finish by 2022 (Table 1).
| Sr. no | Drug | Disease | Disease model used | Results obtained | References |
|-------|------|---------|--------------------|------------------|------------|
| 1     | Telmisartan | Alzheimer’s Disease (AD) Neuroinflammation | Lipopolysaccharide- (LPS-) induced microglia 5XFAD mouse model | ↓ amyloidosis (Aβ (1-40), amyloid plaques) ↓ cerebral blood flow ↓ neuroinflammation (↓AβO-IL-1β, TNF-α, and NF-κb expression) ↓ microgliosis, ↓ astrogliosis | [97–99] |
|       |       | Parkinson’s disease (PD) | Rotenone-induced PD | ↓ ER stress-mediated neuronal apoptosis | [100] |
|       |       | Cognitive impairment and vascular dementia | Chronic cerebral hypoperfusion, MWM | ↑ spatial memory and learning ↓ neuronal loss ↑ PPARy | [103, 104] |
|       |       | Acute and chronic stress | PAT, ORT, OFT, EPM, FST | Upregulation of brain-derived neurotrophic factor (BDNF) gene expression | [105, 106] |
|       |       | Diabetes-induced cognitive decline and depression | FST | ↓ proinflammatory mediators | [70, 107, 108] |
|       |       | Cerebral ischemia-induced impairment of spatial memory | Eight-arm radial maze | Anti-inflammatory—partial PPARγ agonist | [109] |
|       |       | Traumatic brain injury (TBI) | Cortical impact injury in mice brain | Reduction in lesion volume and conservation of the hippocampus | [110] |
|       |       | Epilepsy | Maximal electroshock and PTZ-induced seizure in mice | Antiepileptic | [88, 111, 112] |
|       |       | PRoFESS (Prevention Regimen for Effectively Avoiding Second Strokes) AD (ongoing) NCT02085265; NCT02471833 | Patients—20332 (aged 67) (acute mild ischemic stroke and mildly elevated BP) | 1360 patients appeared safe | [113, 114] |
| Sr. no | Drug       | Disease                                                                 | Disease model used                                                                 | Results obtained                                                                                           | References |
|-------|------------|------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|------------|
| 2     | Losartan   | AD and cognitive impairment                                            | Aβ peptide oligomerization assay, T maze, MWM, PAT, NOR, FST, EPM, MBT, Hebb-Williams maze (rectangular maze), amyloid-β precursor protein- (APP J20) induced AD | ↓ neuroinflammation (↓ astrogliosis, ↓ microgliosis) <br>↓ plaque number and tau phosphorylation <br>↓ oxidative stress and inflammation <br>↓ cognition and memory, neurogenesis | [115–122] |
|       |            | Parkinon's disease (PD)                                                | MPTP- and 6-OHDA-induced PD in C57BL/6 mice (α-syn-based model)                      | Protect dopaminergic neurons against MPTP toxicity                                                        | [123]      |
|       |            | Learning and memory                                                    | OFT, EPM, SPT                                                                         | Improve cognition function, ↓ oxidative stress and inflammation                                          | [124, 125] |
| 2     | Valsartan  | Epilepsy                                                               | Lithium pilocarpine-induced epilepsy                                                  | Attenuate inflammation and oxidative stress, and exhibit neuroprotective effects                        | [126–128] |
|       |            | Comorbid (hypertension and epilepsy)                                   | Neuronal damage in the hippocampus                                                   | Anti-epileptic (neuroprotection selectively in the CA1 area of the hippocampus)                          | [129]      |
| 3     |            | Cognitive impairment associated with epilepsy                           | Neuronal damage in the hippocampus                                                   | Antidepressant and anxiolytic                                                                          | [117, 130–132] |
|       |            | Depression and anxiety                                                 | Neuronal damage in the hippocampus                                                   | Antipsychotic (↓ KYNA production)                                                                       | [135]      |
|       |            | TBI (traumatic brain injury)                                           | Controlled cortical impact injury                                                    | ↓ neuronal apoptosis and ER stress, enhance BBB integrity, PPAR-gamma activation <br>↑ cognitive/motor, ↓ cerebral blood flow | [133, 134] |
|       |            | Neurocognitive alteration affecting long-term memory                   | Amphetamine-induced neurocognitive alteration in rats                                  | Antipsychotic (↓ KYNA production)                                                                       | [135]      |
|       |            | RADAR AD (ongoing)                                                     | Patients—228 (55 years with mild to moderate AD)                                      | Assessment of rate of whole-brain atrophy, memory, cognitive function                                  | [136]      |
|       |            | AD NCT02913664                                                        | Tg 2576 mouse model                                                                    | ↓ amyloidosis (↓ plaque load, Aβ oligomerization) <br>Improves spatial learning                        | [98, 115, 137] |
|       |            | Valsartan                                                             | APP/PS1 transgenic mouse model (intranasal)                                          | ↓ Aβ-inflammatory effects                                                                               | [121]      |
|       |            | AD                                                                    | Icv STZ-induced cognitive impairment                                                  | Hippocampal neurogenesis <br>Improves spatial learning <br>↓ acetylcholinesterase activity (increased acetylcholine) | [138]      |
|       |            | Depression and anxiety                                                 | CUMS, FST, OFT, NSF                                                                  | Antidepressant (↑ BDNF protein, ↓ noradrenaline and cortisone)                                           | [139]      |
| Sr. no | Drug     | Disease               | Disease model used                                                                 | Results obtained                                                                 | References          |
|-------|----------|-----------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|---------------------|
|       |          | AD and cognitive impairment | LPS-induced microglia activation (SFXAD mouse model) Tg 2576 mouse model MWM | Anti-inflammatory, neuroprotective ↓ Aβ oligomerization ↓ neuroinflammation (↓ astrogliosis, ↓ microgliosis) Improved cognitive function (spatial memory, ↑ neurogenesis) Improved dementia Protection of dopaminergic neurons Inhibition of the synergistic action between Ang II and 6-OHDA | [99, 140, 141] |
| 4     | Candesartan | PD                   | 6-OHDA-induced PD in rats                                                          | Reduced neuronal loss and restored motor functioning.                             | [142]               |
|       |          | Rotenone-induced PD in rats | MPTP-induced PD in mice                                                            | PPAR-γ activation (partial agonism) Anti-inflammatory Upregulation of iNOS Neurorestorative effect ↑ expression of BDNF and TrkB ↓ stress ↑ memory ↓ lesion volume and conservation of the hippocampus Upregulation of iNOS Neurorestorative effect ↓ nonfatal stroke | [143, 76, 110, 145] |
|       |          | Stress               | Long-term repeated amphetamine administration Tight plastic tubes stress Inhibitory avoidance (IA) and object recognition (OR) | ↓ stress ↑ memory ↓ lesion volume and conservation of the hippocampus Upregulation of iNOS Neurorestorative effect ↓ nonfatal stroke | [144, 110, 145] |
|       |          | TBI                  | Cortical impact injury in mice brain Hypertensive rat stroke model                 | ↓ lesion volume and conservation of the hippocampus Upregulation of iNOS Neurorestorative effect ↓ nonfatal stroke | [145]               |
|       |          | Cognitive impairment postischemic stroke | NOR, SAP, PAT LPS-induced brain injury in rats EPM | ↓ lesion volume and conservation of the hippocampus Upregulation of iNOS Neurorestorative effect ↓ nonfatal stroke | [146–148] |
|       |          | Depression and anxiety |                                                                                   | Anxiolytic and antidepressant                                                      | [131]               |

**Table 1: Continued.**

- **CALIBREX (NCT01984164)**
  - Participants—176 (55 years or older) with mild cognitive impairment (MCI) and hypertension
  - Lower risk of dementia and AD
  - [149]

- **SCOPE AD (ongoing)**
  - Participants—4937 (70 to 89 years), evaluation of cognitive state by specific tests with mild-to-moderate hypertension
  - Hampered initiated cognitive decline
  - [150, 151]
| Sr. no | Drug   | Disease                      | Disease model used | Results obtained                                                                 | References |
|--------|--------|------------------------------|--------------------|----------------------------------------------------------------------------------|------------|
| 5      | Olmesartan | AD and cognition            | MWM                | Anti-inflammatory and antioxidative Prevent β-amyloid-induced vascular dysregulation (↓ ROS, MDA level) Improved Aβ-induced cognitive dysfunction ↓ microvessel leakage (hippocampus and corpus callosum) Restored cognitive decline | [98, 152] |
|        |        | Cognitive impairment        | PAT                |                                                                                  | [153]      |
| 6      | Irbesartan | Schizophrenia               | In vitro model using brain cortex slices | ↓ KYNA production and KAT II activity in the rat brain cortex                      | [154]      |
| 7      | Eprosartan | Early AD                    | C57bl/6j and AβPP/PS1/Alzheimer’s disease mice Ang II infusion in the brain of AD mice | Improved cerebral blood flow and connectivity                                      | [156]      |
| 8      | Perindopril | AD and cognitive impairment | Icv administration of amyloid-β (Aβ)1-40 induced AD mice Y-maze test | ↓ oxidative stress Suppression of microglia/astrocyte activation                      | [82]       |
|        |        | PD                           | MPTP mouse model   | Neuroprotection (inhibition of dopamine cell loss) Modulate BDNF                   | [159, 160] |
|        |        | Vascular cognitive impairment| Chronic cerebral hypoperfusion in rats | Protect against neuroinflammation and oxidonitrosative stress                      | [161, 162] |
|        | Oscar  | Patients—25745 (aged 50 yrs) with cognitive decline | In vivo model using brain cortex slices | Improvement of cognitive function                                                  | [157, 158] |
|        |        | Oscar Patients—25745 (aged 50 yrs) with cognitive decline | PROGRESS (Perindopril Protection against Recurrent Stroke Studies) | Participants—6105 (previous stroke or transient ischemic attack) Evaluation of cognitive state by specific tests Measurement of visuospatial, attention, and verbal memory, problem solving, learning, and reasoning | [163–166] |
|        |        | Oscar Patients—25745 (aged 50 yrs) with cognitive decline | CANTAB (Cambridge Neuropsychological Test Automated Battery) | Improved cognition Reduced risk of AD                                              | [167, 168] |
| Sr. no | Drug   | Disease       | Disease model used                                          | Results obtained                                                                 | References          |
|--------|--------|---------------|------------------------------------------------------------|-----------------------------------------------------------------------------------|---------------------|
| 9      | Captopril | AD            | LPS-induced microglia activation                            | ↓ amyloidogenic processing                                                        | [169]               |
|        |        |               | T-maze test                                                | Antioxidant (↓ oxidative/nitrosative stress)                                       |                     |
|        |        |               |                                                            | ↓ inflammation, ↓ Aβ plaque accumulation                                          | [170]               |
|        |        | PD            | MPTP-induced PD model                                      | Protect dopamine cell from degeneration                                           | [78, 171]          |
|        |        | Epilepsy      | PTZ-induced seizures                                        | ↓ seizures and protection against postseizure neuroinjury in the hippocampus     |                     |
|        |        | Depression    | CUMS, chronic social defeat stress model                   | Antidepressant (BK-dependent activation of mTOR1)                                 | [172]               |
| 10     | Lisinopril | AD            | STZ-induced dementia                                       | ↓ oxidative damage and neuroinflammation                                          | [173]               |
|        |        |               |                                                           | PPAR-γ modulation                                                                |                     |
|        |        | Tardive dyskinesia | Haloperidol-induced stereotypic behavior                  |                                                                                   |                     |
| 11     | Trandolapril | Huntington’s disease | 3-Nitropropionic acid-induced Huntington’s disease   | 3-Nitropropionic acid-induced Huntington’s disease   | [174]               |
|        |        |               | EPM, MWM, narrow beam test, locomotor activity             | Neuroprotection                                                                   |                     |
| 12     | Zofenopril | Cerebral ischemia | Bilateral coronary artery occlusion in rats. Biochemical analysis for the level of NO, SOD, and TAC | ↓ TOS and MDA levels                                                              | [175]               |
|        |        | Epilepsy      | Auditory stimulation model                                 | Antiepileptic activity                                                            |                     |
| 13     | Fosinopril | Amnesia       | Scopolamine amnesia in rats, SPA, EPM, MWM                 | Antiamnesic activity                                                              | [176]               |
|        |        | Epilepsy      | Audiogenic seizures                                        | Antiepileptic                                                                     |                     |
| 14     | Ramipril | Cognitive impairment | Radiation-induced cognitive impairment, NOR                  | Potentiated ACE2/Ang-MasR axis                                                    | [177]               |
|        |        | HOPE Stroke   | Women with Vascular/Diabetic disorder—2480 (age—35 yrs and more) with vascular disease or diabetes | ↓ microglial activation                                                           |                     |
|        |        | Stroke        |                                                            | ↓ incidence of fatal and nonfatal stroke                                          | [180]               |
| 15     | Aliskiren | Ischemic stroke | Middle cerebral artery occlusion in mice                   | Neuroprotection, reduced infarct volume, and brain edema formation                | [181]               |
|        |        | Epilepsy      | MES-induced seizures in mice                               | Enhances the anticonvulsant effect of AEDs in mice                                 |                     |

*Table 1: Continued.*
| Sr. no | Drug             | Disease                      | Disease model used                                        | Results obtained                                                                 | References |
|-------|------------------|------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------------------|------------|
| 16    | EMA 300, EMA 200 molecule 20 | Pain                        | Unilateral chronic constriction injury of the sciatic nerve | Inhibit P38 and p42/p44 MAPK (inhibition of metabolism of bradykinin and substance P) | [184]      |
|       | EMA 401          | EMPHEN trial                 | Patients with postherpetic neuralgia                      | No beneficialeffects of AT2R are observed in pain                                  | [185]      |

Abbreviations: AD: Alzheimer's disease; PD: Parkinson's disease; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PAT: passive avoidance test; ORT: object recognition test; OFT: open field test; EPM: elevated plus maze; FST: forced swim test; MBS: maximal electroshock; MWM: Morris water maze; CUMS: chronic unpredictable model of stress; PTZ: pentyleneetrazol; NOR: novel object recognition; SPT: sucrose preference test; 6-OHDA: 6-hydroxyl dopamine.
Kehoe et al. [84] studied human postmortem brain tissue and CSF of AD, diseased, and noncontrolled patients. The authors measured ACE1 and ACE2 activity by using an ACE1-specific fluorogenic peptide substrate (Abz-Frkd(Dnp)-P) and ACE2-specific fluorogenic peptide substrate (mca-AKP(Dnp)) in the presence of a specific ACE1 inhibitor, captopril, and a ACE2 inhibitor, MLN4760, respectively. Angiotensin I and II and Ang (1-7) were measured by the direct ELISA method. The authors found ACE overactivity in brain RAS, and postmortem CSF in AD is mirrored in antemortem CSF. CSF-ACE1 in AD is higher in CSF-t-tau and CSF-p-tau but not CSF-AF-42. In contrast to brain tissues, ACE2 positively correlates with ACE1 activity in post- and antemortem CSF (inverse correlation in brain and brain tissue). Brain angiotensin changes in AD are not reflected in CSF. These findings indicated that some markers of brain RAS are mirrored in CSF; however, the relationship is complex. The recent research work by Evans et al. [85] has indicated beneficial effects of diminazene aceturate (ACE2 activator) by enhancement of brain ACE2 activity thereby lowering hippocampal Aβ and hence restoring cognition in symptomatic Tg2576 mice.

2.8.9. Role of Brain RAS in Stress, HPA Axis Regulation, and Depression. AT1 receptors are majorly distributed in areas that control stress response such as SFO and the median eminence in the hypothalamic PVN, anterior pituitary gland, amygdala and septal nuclei, hippocampus, and NTS [86]. Stress results in the formation of Ang II in the thalamus and other parts of the brain that contribute to catecholamine release [87].

Brain RAS has already proven to have a role in the pathophysiology of depression [70]. As AT1 and AT2 receptors are found in the hypothalamus-pituitary-adrenal (HPA) [88] axis, HPA plays an important role in stress and stress-related behavior. Activation of corticotropin-releasing hormone (CRH) gene expression was found via AT1 receptor activation in immobilization-induced stress. Treatment with ARB (telmisartan, candesartan, and valsartan) or ACE inhibitors reduces CRH-induced adrenocorticotropic hormone (ACTH) and corticosterone release in spontaneously hypertensive rats. They also decreased pituitary sensitivity to CRH and reduced hypothalamic CRH expression which ultimately led to the reduction of stress [89] (Table 1). However, preclinical ARBs and ACEI are found to be effective. Clinical studies on them with respect to depression are still awaited.

2.8.10. Role of Brain RAS in Alcohol Addiction. Alcohol consumption is majorly dependent on social aspects along with genetic factors that play a crucial role in the pathogenesis of alcohol addiction. Experimental studies suggested that there is a direct correlation between endogenous Ang II level and voluntary alcohol consumption [90]. The reward circuitry (activated due to alcohol consumption) of the brain has dopamine as a critical component; accordingly, genetically modified D2 receptor-deficient mice have been shown to drink less alcohol [91]. Angiotensin receptors are expressed in the dopaminergic dominated nucleus accum-bens; also, Ang II is demonstrated to stimulate dopamine release in the brain [92]. The central administration of Ang II to the experimental animal increased alcohol intake. ACE inhibitors, captopril and enalapril, therefore are found to prevent alcohol consumption [93].

2.8.11. Role of Brain RAS in Pain. Pain is defined as hyperexcitation of sensory neurons that arises because of injury, trauma, inflammation, and nerve damage. Ang II injection into mouse hind paw has shown the development of peripheral pain. The amygdala, hypothalamus, and frontoparietal cortex are considered to be important parts in the relay of pain which also expresses RAS receptors. The drugs blocking RAS have been shown to inhibit and show potential benefits in central pain originating from either the brain or spinal cord such as migraine and neuropathy pain. The mechanism predicted is inhibition of cytokines and also due to the release of endogenous opioids. The literature also reports contradictory effects of brain RAS and ACEI which has shown an algesic effect due to inhibition of metabolism of bradykinin and substance P, while recent studies showed the antinociceptive effect of ACEI and ARBs by attenuating substance P, NO, and calcitonin gene-related peptide (CGRP). Newer drug candidates such as AT2R antagonists, EMA 200, EMA 300, EMA 401 have shown to inhibit P38 and p42/p44 MAPK; hence, they are found to be beneficial in neuropathic pain; however, the recent article published in June 2020 indicated that the AT2 receptor does not have any role to play in pain modulation [72, 94].

The early phase Ib clinical study on EMA 401, an AT2R antagonist, was found to be effective in neuropathic pain (Spinifex Pharmaceuticals) though the detailed clinical study results are awaited as the phase II clinical trial EPHENE was terminated due to lack of preclinical safety data (Table 1).

There is a lack of literature, and the unavailability of clinical trials on these molecules makes them obscure. Moreover, poor penetrability through BBB is another challenge to target brain AT2 receptors. Hence, there is need to synthesize and develop more analogs and perform exhaustive preclinical studies to explore their potential in CNS-mediated pain-related disorders [95].

2.8.12. SARS-CoV-2 Infection and Neurological Manifestations. Current threat of COVID-19, which has agitated the whole world, is an infectious disease caused by severe acute respiratory syndrome nCoV-2 (SARS CoV-2). COVID-19 has caused enormous deaths which have been reported worldwide. Symptoms associated resemble normal viral infection except in severe condition; it may develop to pneumonia, acute respiratory distress syndrome (ARDS), and multiorgan failure. SARS-CoV-2 consists of S protein (structural protein) which is multifunctional and plays a vital role in host receptor binding and pathogenesis of the virus. Postentry, there are a release of the viral RNA genome in the cytoplasm and translation into 2 polyproteins as well as structural proteins, and later replication of the viral genome begins. The membrane of the endoplasmic reticulum (ER) or Golgi is then inserted with newly formed unglycosylated proteins, and then, development of viral particles

Journal of the Renin-Angiotensin-Aldosterone System

13
into the ER-Golgi intermediate compartment takes place followed by fusion of the plasma membrane with vesicles containing viral particles leading to the release of the virus. Apart from lung and cardiovascular tissues, newly assembled SARS-CoV-2 virions infect the ACE2-expressing cells on neuronal and glial cells in the brain. It also enters the brain predominantly through the olfactory mucosa (the first feature is the development of anosmia) and could spread through neuroanatomical interconnection. Within the CNS, the brain stem is worst affected leading to respiration and cardiovascular impairment and death. The acute infection of the brain is characterized by delirium followed by severe conditions such as unconsciousness, cerebrovascular events (stroke), encephalopathy, and seizures. The chronic conditions associated with brain RAS.

3. Conclusion

Since the conception of brain RAS in the year 1898, continuous research has been done in the field. It is now very well established that brain RAS plays a crucial role in CNS-controlled cardiovascular function, thirst, and maintenance of sodium level; also, it exhibits a prominent role in CNS itself. It is a neuroprotectant, observed via activation of the AT2 receptor; on the contrary, AT1 receptor activation has been shown to induce oxidative stress. Therefore, AT2 receptor agonists and AT1 receptor antagonists play a crucial role in cerebral protection. Similarly, blocking of AT1 receptors on dopaminergic neurons by ARBs and ACEI demonstrated a potent anti-PD effect. The role of Ang IV in the memory-enhancing effect is well established, though the invention of the Ang IV agonist is still awaited. ACE overexpression is found to be associated with AD, and its inhibition by perindopril and captopril has shown a promising effect in AD preclinically. The myriad of clinical trials on ARBs and ACEI are evident that indicate the possible clinical use of these drugs in AD in the near future. ACEI and ARBs are also found to be effective in depression by ameliorating the HPA axis. Recently, the role of brain RAS has been studied in the development of addiction. There is scope for more research on brain RAS in addiction and substance abuse, epilepsy, stress-related disorder, and psychosis. Recent literature also reported the analgesic effect of AT2R antagonists though still there is a need for preclinical and clinical studies to prove its clinical benefit. With a plethora of preclinical studies available for brain RAS, the unavailability of clinical trials on molecules modulating brain RAS obscures them. We have summarized the preclinical and clinical research work carried out using angiotensin enzyme and receptor inhibitors. However, further studies are needed to unfold the uses of these molecules in various pathological conditions associated with brain RAS.

Data Availability

It is a review article; hence, there is no data which was generated in the laboratory.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors would like to acknowledge Dr. A.P. Pawar, Principal, PCP, BVDU, for providing the necessary facilities to prepare the manuscript.

References

[1] R. Tigerstedt and P. Q. Bergman, “Niere und Kreislauf 1,” Skandinavisches Archiv für Physiologie, vol. 8, no. 1, pp. 223–271, 1898.
[2] I. H. Page, “The discovery of angiotensin,” Perspectives in Biology and Medicine, vol. 18, no. 4, pp. 456–463, 1975.
[3] D. Ganten, K. Hayduk, H. M. Brecht, R. Boucher, and J. Genest, “Evidence of renin release or production in splanchnic territory,” Nature, vol. 226, no. 5245, pp. 551–552, 1970.
[4] M. Ian Phillips and D. Felix, “Specific angiotensin II receptive neurons in the cat subfornical organ,” Brain Research, vol. 109, no. 3, pp. 531–540, 1976.
[5] S. Hirose, H. Yokosawa, and T. Inagami, “Immunohistochemical identification of renin in rat brain and distinction from acid proteases,” Nature, vol. 274, no. 5669, pp. 392–393, 1978.
[6] M. I. Phillips, “Angiotensin in the brain,” Neuroendocrinology, vol. 25, no. 6, pp. 354–377, 1978.
[7] M. P. Printz, J. A. Lewicki, and C. J. Wallis, Brain angiotensinogen: origin and evidence for an influence by adrenal corticosteroids. Enzymatic release of vasoactive peptides, Raven, New York, 1980.
[8] M. Roth, A. F. Weitzman, and Y. Piquilloud, “Converting enzyme content of different tissues of the rat,” Experientia, vol. 25, no. 12, p. 1247, 1969.
[9] H.-Y. T. Yang and N. H. Neff, “Distribution and properties of angiotensin converting enzyme of rat brain,” Journal of Neurochemistry, vol. 19, no. 10, pp. 2443–2450, 1972.
[10] D. Ganten, K. Hermann, C. Bayer, T. Unger, and R. E. Lang, “Angiotensin synthesis in the brain and increased turnover in hypertensive rats,” Science, vol. 221, no. 4613, pp. 869–871, 1983.
[11] K. Hermann, M. K. Raizada, C. Summers, and M. I. Phillips, “Presence of renin in primary neuronal and glial cells from rat brain,” Brain Research, vol. 437, no. 2, pp. 205–213, 1987.
[12] M. I. Phillips and B. Stenstrom, “Angiotensin II in rat brain comigrates with authentic angiotensin II in high pressure liquid chromatography,” Circulation Research, vol. 56, no. 2, pp. 212–219, 1985.
[13] R. L. Storrona, C. L. Hawelu-Johnson, P. G. Guyenet, and K. R. Lynch, “Astrocytes synthesize angiotensinogen in brain,” Science, vol. 242, no. 4884, pp. 1444–1446, 1988.
[14] J. L. Labandeira-Garcia, A. I. Rodriguez-Perez, P. Garrido-Gil, J. Rodriguez-Pallares, J. L. Lanciego, and M. J. Guerra, “Brain renin-angiotensin system and microglial polarization:
implications for aging and neurodegeneration,” *Frontiers in Aging Neuroscience*, vol. 9, p. 129, 2017.

[15] J. Rodriguez-Pallares, P. Rey, J. A. Parga, A. Muñoz, M. J. Guerra, and J. L. Labandeira-García, “Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS,” *Neurobiology of Disease*, vol. 31, no. 1, pp. 58–73, 2008.

[16] R. Valenzuela, M. A. Costa-Besada, J. Ilegias-Gonzalez et al., “Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration,” *Cell Death & Disease*, vol. 7, no. 10, pp. e2427–e2427, 2016.

[17] H. Ohkubo, R. Kageyama, M. Ujihara, T. Hirose, S. Inayama, and S. Morimoto, “Cloning and sequence analysis of cDNA for rat angiotensinogen,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 80, no. 8, pp. 2196–2200, 1983.

[18] C. F. Deschepper, J. Bouhnik, and W. F. Ganong, “Colocalization of angiotensinogen and glial fibrillary acidic protein in astrocytes in rat brain,” *Brain Research*, vol. 374, no. 1, pp. 195–198, 1986.

[19] G. Yang, T. S. Gray, C. D. Sigmund, and M. D. Cassell, “The angiotensinogen gene is expressed in both astrocytes and neurons in murine central nervous system,” *Brain Research*, vol. 817, no. 1–2, pp. 123–131, 1999.

[20] S. Morimoto, M. D. Cassell, and C. D. Sigmund, “The brain renin-angiotensin system in transgenic mice carrying a highly regulated human renin transgene,” *Circulation research*, vol. 90, no. 1, pp. 80–86, 2002.

[21] J. L. Lavoie, X. Liu, R. A. Bianco, T. G. Beltz, A. K. Johnson, and C. D. Sigmund, “Evidence supporting a functional role for intracellular renin in the brain,” *Hypertension*, vol. 47, no. 3, pp. 461–466, 2006.

[22] W. Cao, A. Li, J. Li et al., “Reno-cerebral reflex activates the renin-angiotensin system, promoting oxidative stress and renal damage after ischemia-reperfusion injury,” *Antioxidants & Redox Signaling*, vol. 27, no. 7, pp. 415–432, 2017.

[23] M.-O. Guimond and N. Gallo-Payet, “The angiotensin II type 2 receptor in brain functions: an update,” *International Journal of Hypertension*, vol. 2012, Article ID 351758, 18 pages, 2012.

[24] A. Reaux-le Goazigo, I. Iturrioz, C. Fassot, C. Claperon, B. P. Roques, and C. Llorens-Cortes, “Role of angiotensin III in hypertension,” *Current Hypertension Reports*, vol. 7, no. 2, pp. 128–134, 2005.

[25] J. W. Wright, E. Tamura-Myers, W. L. Wilson et al., “Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats,” *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*, vol. 284, no. 3, pp. R725–R733, 2003.

[26] L. Loufrani, D. Henrion, D. Chancel, R. Ardaillou, and B. I. Levy, “Functional evidence for an angiotensin IV receptor in rat resistance arteries,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 291, no. 2, pp. 583–588, 1999.

[27] J. Lee, A. L. Albiston, A. M. Allen et al., “Effect of I.C.V. injection of AT1 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats,” *Neuroscience*, vol. 124, no. 2, pp. 341–349, 2004.

[28] J. Gao, Y. Marc, X. Iturrioz, V. Leroux, F. Balavoine, and C. Llorens-Cortes, “A new strategy for treating hypertension by blocking the activity of the brain renin–angiotensin system with aminopeptidase A inhibitors,” *Clinical Science*, vol. 127, no. 3, pp. 135–148, 2014.

[29] A. Reaux, M. C. Fournie-Zaluski, C. David et al., “Aminopeptidase A inhibitors as potential central antihypertensive agents,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 23, pp. 13415–13420, 1999.

[30] V. L. Bodiga and S. Bodiga, “Renin angiotensin system in cognitive function and dementia,” *Asian Journal of Neuroscience*, vol. 2013, Article ID 102602, 18 pages, 2013.

[31] J. L. Grobe, D. Xu, and C. D. Sigmund, “An intracellular renin-angiotensin system in neurons: fact, hypothesis, or fantasy,” *Physiology*, vol. 23, no. 4, pp. 187–193, 2008.

[32] P. Nakagawa and C. D. Sigmund, “How is the brain renin–angiotensin system regulated?,” *Hypertension*, vol. 70, no. 1, pp. 10–18, 2017.

[33] E. G. Erdös, “Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture,” *Hypertension*, vol. 16, no. 4, pp. 363–370, 1990.

[34] S.-G. Wei and R. B. Felder, “Forebrain renin-angiotensin system has a tonic excitatory influence on renal sympathetic nerve activity,” *American Journal of Physiology-Heart and Circulatory Physiology*, vol. 282, no. 3, pp. H890–H895, 2002.

[35] M. Donoghue, H. Hsieh, E. Baronas et al., “A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9,” *Circulation Research*, vol. 87, no. 5, pp. e1–e9, 2000.

[36] S. R. Tipnis, N. M. Hooper, R. Hyde, E. Karran, G. Christie, and A. J. Turner, “A Human Homolog of Angiotensin-converting Enzyme,” *Journal of Biological Chemistry*, vol. 275, no. 43, pp. 33238–33243, 2000.

[37] C. Vickers, P. Hales, V. Kaushik et al., “Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase*,” *Journal of Biological Chemistry*, vol. 277, no. 17, pp. 14838–14843, 2002.

[38] C. M. Ferrario, J. Jessup, M. C. Chappell et al., “Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2,” *Circulation*, vol. 111, no. 20, pp. 2605–2610, 2005.

[39] R. A. S. Santos, A. J. Ferreira, and A. C. Simões e Silva, “Recent advances in the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axis,” *Experimental Physiology*, vol. 93, no. 5, pp. 519–527, 2008.

[40] Y. Tagil and C. Yagil, “Hypothesis: ACE2 modulates blood pressure in the mammalian organism,” *American Heart Association*, vol. 41, no. 4, pp. 871–873, 2003.

[41] A. Lippoldt, M. Paul, K. Fuxe, and D. Ganten, “The brain renin-angiotensin system: molecular mechanisms of cell to cell interactions,” *Clinical and Experimental Hypertension*, vol. 17, no. 1–2, pp. 251–266, 1995.

[42] H. Urata, B. Healy, R. W. Stewart, F. M. Bumpus, and A. Husain, “Angiotensin II-forming pathways in normal and failing human hearts,” *Circulation Research*, vol. 66, no. 4, pp. 883–890, 1990.

[43] I. Banegas, I. Prieto, F. Vives et al., “Brain aminopeptidases and hypertension,” *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 7, no. 3, pp. 129–134, 2006.

[44] K. D. Singh and S. S. Karnik, “Angiotensin receptors: structure, function, signaling and clinical applications,” *Journal of Cell Signaling*, vol. 1, no. 2, 2016.
[54] J. Iwai, Y. Kanayama, N. N. T. Inoue, M. Okamura, and T. Takeda, "Increased endothelial gene expression of angiotensin AT1 receptor in cyclosporine induced hypertensive rats," European Journal of Pharmacology: Environmental Toxicology and Pharmacology, vol. 248, no. 4, pp. 341–344, 1993.

[56] L. K. Becker, G. M. Etelvino, T. Walther, R. A. S. Santos, and M. J. Campagnole-Santos, "Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain," American Journal of Physiology-Heart and Circulatory Physiology, vol. 293, no. 3, pp. H1416–H1424, 2007.

[57] H. Stauss and T. Unger, "Role of angiotensin in the drinking response after water deprivation," Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 343, p. R106, 1990.

[58] D. R. Gehlert, S. L. Gackenheimer, J. K. Reel, Ho-Shen Lin, and M. I. Steinberg, "Non-peptide angiotensin II receptor antagonists discriminate subtypes of angiotensin II binding sites in the rat brain," European Journal of Pharmacology, vol. 187, no. 1, pp. 123–126, 1990.

[59] A. D. de Kloet, U. M. Steckelings, and C. Summers, "Protective angiotensin type 2 receptors in the brain and hypertension," Current Hypertension Reports, vol. 19, no. 6, p. 46, 2017.

[60] M. Mogi, J.-M. Li, J. Iwamori et al., "Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2," Hypertension, vol. 48, no. 1, pp. 141–148, 2006.

[61] K. Bedecs, N. Elbaz, M. Sutren et al., "Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase," Biochemical Journal, vol. 325, no. 2, pp. 449–454, 1997.

[62] M. Horiuichi, W. Hayashida, T. Kambe, T. Yamada, and V. J. Dzau, "Angiotensin Type 2 Receptor Dephosphorylates Bcl-2 by Activating Mitogen-activated Protein Kinase Phosphatase-1 and Induces Apoptosis," Journal of Biological Chemistry, vol. 272, no. 30, pp. 19022–19026, 1997.

[63] U. V. Shenoy, E. M. Richards, X.-C. Huang, and C. Summers, "Angiotensin II type 2 receptor-mediated apoptosis of cultured neurons from newborn rat brain," Endocrinology, vol. 140, no. 1, pp. 500–509, 1999.

[64] S. S. Karnik, K. D. Singh, K. Tirupula, and H. Unal, "Significance of angiotensin 1–7 coupling with MAS receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22," British Journal of Pharmacology, vol. 174, no. 9, pp. 737–753, 2017.

[65] I. Moeller, D. H. Small, G. Reed, J. W. Harding, F. A. O. Mendelsohn, and S. Y. Chai, "Angiotensin IV inhibits neurite outgrowth in cultured embryonic chicken sympathetic neurones," Brain research, vol. 725, no. 1, pp. 61–66, 1996.

[66] J. Lee, S.-Y. Chai, F. A. O. Mendelsohn, J. M. Morris, and A. M. Allen, "Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7," Neuropharmacology, vol. 40, no. 4, pp. 618–623, 2001.

[67] X. Yang, F. Wang, H. Chang et al., "Autoantibody against AT1 receptor from preeclamptic patients induces vasocostriction through angiotensin receptor activation," Journal of Hypertension, vol. 26, no. 8, pp. 1629–1635, 2008.

[68] G. N. Swanson, J. M. Hanesworth, M. F. Sardinia et al., "Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor," Regulatory Peptides, vol. 40, no. 3, pp. 409–419, 1992.

[69] D. Young, K. O'Neill, T. Jessell, and M. Wigler, "Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain," Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 14, pp. 5339–5342, 1988.

[70] G. M. Etelvino, A. A. B. Peluso, and R. A. S. Santos, "New components of the renin-angiotensin system: alamandine and the MAS-related G protein-coupled receptor D," Current Hypertension Reports, vol. 16, no. 6, p. 433, 2014.

[71] C. Peiró and S. Moncada, "Substituting angiotensin-(1-7)/Mas receptor axis for treating patients with COVID-19," International Journal of Infectious Diseases, vol. 96, pp. 348–351, 2020.

[72] U. M. Steckelings, N. Obermüller, S. P. Bottari, F. Qadri, A. Veltmar, and T. Unger, "Brain angiotensin: receptors, actions and possible role in hypertension," Pharmacology & Toxicology, vol. 70, no. S6, pp. s23–s27, 1992.

[73] G. Huber, F. Schuster, and W. Raasch, "Brain renin-angiotensin system in the pathophysiology of cardiovascular diseases," Pharmacological Research, vol. 125, Part A, pp. 72–90, 2017.

[74] M. I. Phillips and E. M. de Oliveira, "Brain renin angiotensin in disease," Journal of Molecular Medicine, vol. 66, no. 6, pp. 715–722, 2008.

[75] J. Culman, T. Jacob, S. O. Schuster et al., "Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?," Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 390, no. 9, pp. 949–959, 2017.

[76] M. M. C. Arroja, E. Reid, and C. McCabe, "Therapeutic potential of the renin angiotensin system in ischaemic stroke," Experimental & Translational Stroke Medicine, vol. 8, no. 1, pp. 1–14, 2016.

[77] U. Aswar, S. Chetupwar, S. Shintre, and M. Aswar, "Telmisartan attenuates diabetes induced depression in rats," Pharmacological Reports, vol. 69, no. 2, pp. 358–364, 2017.

[78] A. Nguyen Dinh Cat, A. C. Montezano, D. Burger, and R. M. Touyz, "Angiotensin II, NADPH oxidase, and redox signaling in the vasculature," Antioxidants & Redox Signaling, vol. 19, no. 10, pp. 1110–1120, 2013.

[79] M. T. Smith, B. D. Wyse, and S. R. Edwards, "Small molecule angiotensin II type 2 receptor (AT2R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats," Pain Medicine, vol. 14, no. 5, pp. 692–705, 2013.

[80] K. K. Griendling, D. Sorescu, and M. Ushio-Fukai, "NAD (P)H oxidase: role in cardiovascular biology and disease," Circulation Research, vol. 86, no. 5, pp. 494–501, 2000.
[74] P. K. Prusty, P. Sahu, and B. Subudhi, “Angiotensin mediated oxidative stress and neuroprotective potential of antioxidants and AT1 receptor blockers,” *Mini Reviews in Medicinal Chemistry*, vol. 17, no. 6, pp. 518–528, 2017.

[75] J. W. Wright and J. W. Harding, “Importance of the brain angiotensin system in Parkinson’s disease,” *Parkinson’s Disease*, vol. 2012, Article ID 860923, 14 pages, 2012.

[76] P. Garrido-Gil, B. Joglar, A. I. Rodriguez-Perez, M. J. Guerra, and J. L. Labandeira-Garcia, “Involvement of PPAR-y in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson’s disease,” *Journal of Neuroinflammation*, vol. 9, no. 1, pp. 1–16, 2012.

[77] A. Moradganjeh, S. A. Ziai, and M. Roghani, “Losartan pretreatment reduces neurodegeneration and behavioural symptoms in 6-hydroxydopamine induced unilateral rat model of Parkinson’s disease,” *Pathophysiology*, vol. 20, no. 4, pp. 243–248, 2013.

[78] A. L. Albiston, R. Fernando, S. Ye, G. R. Peck, and S. Y. Chai, “Alzheimer’s, angiotensin IV and an aminopeptidase,” *Biological and Pharmaceutical Bulletin*, vol. 27, no. 6, pp. 765–767, 2004.

[79] J. Royea, P. Martinot, and E. Hamel, “Memory and cerebrovascular deficits recovered following angiotensin IV intervention in a mouse model of Alzheimer’s disease,” *Neurobiology of Disease*, vol. 134, p. 104644, 2020.

[80] S.-S. Zhan, W. Kamphorst, W. E. van Nostrand, and I. Armando, A. Seltzer, C. Bregonzio, and J. Saavedra, “K. Yamada, S. Uchida, S. Takahashi et al., “K. Prusty, P. Sahu, and B. Subudhi,” *Journal of the Renin-Angiotensin-Aldosterone System*.

[81] P. K. Sonsalla, C. Coleman, L.-Y. Wong et al., “The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism,” *Experimental Neurology*, vol. 250, pp. 376–383, 2013.

[82] K. Prusty, P. Sahu, and B. Subudhi, “K. Prusty, P. Sahu, and B. Subudhi,” *Journal of the Renin-Angiotensin-Aldosterone System*.

[83] A. L. Albiston, R. Fernando, S. Ye, G. R. Peck, and S. Y. Chai, “Alzheimer’s, angiotensin IV and an aminopeptidase,” *Biological and Pharmaceutical Bulletin*, vol. 27, no. 6, pp. 765–767, 2004.

[84] J. Royea, P. Martinot, and E. Hamel, “Memory and cerebrovascular deficits recovered following angiotensin IV intervention in a mouse model of Alzheimer’s disease,” *Neurobiology of Disease*, vol. 134, p. 104644, 2020.

[85] S.-S. Zhan, W. Kamphorst, W. E. van Nostrand, and P. Eikelenboom, “Distribution of neuronal growth-promoting factors and cytoskeletal proteins in altered neurites in Alzheimer’s disease and non-demented elderly,” *Acta Neuropathologica*, vol. 89, no. 4, pp. 356–362, 1995.

[86] Y.-F. Dong, K. Kataoka, Y. Tokutomi et al., “Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease,” *The FASEB Journal*, vol. 25, no. 9, pp. 2911–2920, 2011.

[87] K. Yamada, S. Uchida, S. Takahashi et al., “Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease,” *Brain Research*, vol. 1352, pp. 176–186, 2010.

[88] P. G. Kehoe, N. al Mulhim, H. Zetterberg, K. Blennow, and J. S. Miners, “Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer’s Disease,” *Journal of Alzheimer’s Disease*, vol. 72, no. 2, pp. 525–535, 2019.

[89] C. E. Evans, J. S. Miners, G. Piva et al., “Correction to: ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease,” *Acta Neuropathologica*, vol. 140, no. 5, p. 791, 2020.

[90] I. Armando, A. Seltzer, C. Bregonzio, and J. Saavedra, “Stress and angiotensin II: novel therapeutic opportunities,” *Current Drug Targets-CNS & Neurological Disorders*, vol. 2, no. 6, pp. 413–419, 2003.

[91] J. M. Saavedra and J. Benicky, “Brain and peripheral angiotensin II play a major role in stress,” *Stress*, vol. 10, no. 2, pp. 185–193, 2007.

[92] V. H. Pushpa, P. Shetty, R. N. Suresha, M. K. Jayanthi, V. Ashwini, and P. S. Vaibhavi, “Evaluation and comparison of anticonvulsant activity of telmisartan and olmesartan in experimentally induced animal models of epilepsy,” *Journal of Clinical and Diagnostic Research: JCDR*, vol. 8, no. 10, p. HC08, 2014.

[93] H. Müller, J. Kröger, O. Jöhren et al., “Stress sensitivity is increased in transgenic rats with low brain angiotensinogen,” *Journal of endocrinology*, vol. 204, no. 1, p. 85, 2010.

[94] B. Maul, W.-E. Siems, M. R. Hoehe, G. Grecksch, M. Bader, and T. Walther, “Alcohol consumption is controlled by angiotensin II,” *The FASEB Journal*, vol. 15, no. 9, pp. 1640–1642, 2001.

[95] T. J. Phillips, K. J. Brown, S. Burkart-Kasch et al., “Alcohol preference and sensitivity are markedly reduced in mice lacking dopamine D2 receptors,” *Nature Neuroscience*, vol. 1, no. 7, pp. 610–615, 1998.

[96] F. A. O. Medelsohn, T. A. Jenkins, and S. F. Berkovic, “Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats,” *Brain research*, vol. 613, no. 2, pp. 221–229, 1993.

[97] D. Daniels and D. Daniels, “Thirst and water balance,” *Oxford Research Encyclopedia of Neuroscience*, 2019.

[98] C. J. A. Sigrist, A. Bridge, and P. le Mercier, “A potential role for integrins in host cell entry by SARS-CoV-2,” *Antiviral Research*, vol. 177, p. 104759, 2020.

[99] L. Juillerat-Jeanneret, “The other angiotensin II receptor: AT2R as a therapeutic target,” *Journal of Medicinal Chemistry*, vol. 63, no. 5, pp. 1978–1995, 2020.

[100] G. Vargas, L. H. Medeiros Geraldo, N. Gedeão Salomão, M. Viana Paes, F. Regina Souza Lima, and F. Carvalho Alcantara Gomes, “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and glial cells: insights and perspectives,” *Brain, Behavior, & Immunity-Health*, vol. 7, article 100127, 2020.

[101] C. Jang, J. Kim, Y. Kwon, and S. A. Jo, “Telmisartan inhibits TNFα-induced leukocyte adhesion by blocking ICAM-1 expression in astroglial cells but not in endothelial cells,” *Biomolecules & Therapeutics*, vol. 28, no. 5, pp. 423–430, 2020.

[102] Z.-F. Wang, J. Li, C. Ma, C. Huang, and Z.-Q. Li, “Telmisartan ameliorates Aβ oligomer-induced inflammation via PPARγ/PTEN pathway in BV2 microglial cells,” *Biochemical Pharmacology*, vol. 171, p. 113674, 2020.

[103] N. Torika, K. Asraf, A. Danon, R. N. Apte, and S. Fleisher-Berkovich, “Telmisartan modulates glial activation: in vitro and in vivo studies,” *PLoS One*, vol. 11, no. 5, article e0155823, 2016.

[104] Q. Tong, L. Wu, T. Jiang, Z. Ou, Y. Zhang, and D. Zhu, “Inhibition of endoplasmic reticulum stress-activated IRE1α/PERK pathway is involved in the neuroprotective effects of telmisartan in the rotenone rat model of Parkinson’s disease,” *European Journal of Pharmacology*, vol. 776, pp. 106–115, 2016.

[105] S. Sathyia, V. Ranju, P. Kalaivani et al., “Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice,” *Neuropharmacology*, vol. 73, pp. 98–110, 2013.

[106] S. Sekar, S. Mani, B. Rajamani et al., “Telmisartan ameliorates astroglial and dopaminergic functions in a mouse model of...
chronic parkinsonism,” *Neurotoxicity Research*, vol. 34, no. 3, pp. 597–612, 2018.

[103] Y. Gao, W. Li, Y. Liu et al., “Effect of telmisartan on preventing learning and memory deficits via peroxisome proliferator-activated receptor-γ in vascular dementia spontaneously hypertensive rats,” *Journal of Stroke and Cerebrovascular Diseases*, vol. 27, no. 2, pp. 277–285, 2018.

[104] M. Mogi, J.-M. Li, K. Tsukuda et al., “Telmisartan prevented cognitive decline partly due to PPAR-γ activation,” *Biochemical and Biophysical Research Communications*, vol. 375, no. 3, pp. 446–449, 2008.

[105] D. Wincewicz, A. Juchniewicz, N. Waszkiewicz, and J. J. Braszko, “Angiotensin type II type 1 receptor blockade by telmisartan prevents stress-induced impairment of memory via HPA axis deactivation and up-regulation of brain-derived neurotrophic factor gene expression,” *Pharmacology Biochemistry and Behavior*, vol. 148, pp. 108–118, 2016.

[106] D. Wincewicz and J. J. Braszko, “Telmisartan attenuates cognitive impairment caused by chronic stress in rats,” *Pharmacological Reports*, vol. 66, no. 3, pp. 436–441, 2014.

[107] L. Lenart and A. Fekete, “Angiotensin receptor 1 blockade as an antidepressant strategy,” in *The Neuroscience of Depression*, Elsevier, 2021.

[108] L.-J. Min, M. Mogi, M. Shudou et al., “Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice,” *Hypertension*, vol. 59, no. 5, pp. 1079–1088, 2012.

[109] T. Haraguchi, K. Iwasaki, K. Takasaki et al., “Telmisartan, a partial agonist of peroxisome proliferator-activated receptor γ, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia,” *Brain Research*, vol. 1353, pp. 125–132, 2010.

[110] S. Villapol, M. G. Balarezo, K. Affram, J. M. Saavedra, and A. J. Symes, “Neurorestoration after traumatic brain injury through angiotensin II receptor blockade,” *Brain*, vol. 138, no. 11, pp. 3299–3315, 2015.

[111] N. Ivanova and J. Tchekalova, “The potential therapeutic capacity of inhibiting the brain renin–angiotensin system in the treatment of co-morbid conditions in epilepsy,” *CNS Drugs*, vol. 33, no. 11, pp. 1101–1112, 2019.

[112] T. Nozaki, H. Ura, I. Takumi, S. Kobayashi, E. Maru, and A. Morita, “The angiotensin II type 1 receptor antagonist losartan retards amygdala kindling-induced epileptogenesis,” *Brain Research*, vol. 1694, pp. 121–128, 2018.

[113] P. M. W. Bath, R. H. Martin, Y. Palesch et al., “Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PROFESSION subgroup analysis,” *Stroke*, vol. 40, no. 11, pp. 3541–3546, 2009.

[114] H.-C. Diener, R. L. Sacco, S. Yusuf et al., “Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial: a double-blind, active and placebo-controlled study,” *The Lancet Neurology*, vol. 7, no. 10, pp. 875–884, 2008.

[115] J. Royea and E. Hamel, “Brain angiotensin II and angiotensin IV receptors as potential Alzheimer’s disease therapeutic targets,” *GeroScience*, vol. 42, no. 5, pp. 1237–1256, 2020.

[116] H. H. Drews, R. Klein, A. Lourhmati et al., “Losartan improves memory, neurogenesis and cell motility in transgenic Alzheimer’s mice,” *Pharmaceuticals*, vol. 14, no. 2, p. 166, 2021.

[117] H. Salmani, M. Hosseini, Y. Baghchehgi, R. Moradi-Marjaneh, and A. Mokhtari-Zaer, “Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: the role of PPAR-γ activation,” *Cytokine*, vol. 125, p. 154860, 2020.

[118] J. Royea, L. Zhang, X.-K. Tong, and E. Hamel, “Angiotensin IV receptors mediate the cognitive and cerebrovascular benefits of losartan in a mouse model of Alzheimer’s disease,” *Journal of Neuroscience*, vol. 37, no. 22, pp. 5562–5573, 2017.

[119] P. Papadopoulos, X.-K. Tong, H. Imboden, and E. Hamel, “Losartan improves cerebrovascular function in a mouse model of Alzheimer’s disease with combined overproduction of amyloid-β and transforming growth factor-β1,” *Journal of Cerebral Blood Flow & Metabolism*, vol. 37, no. 6, pp. 1959–1970, 2017.

[120] B. Ongali, N. Nicolakakis, X.-K. Tong et al., “Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model,” *Neurobiology of Disease*, vol. 68, pp. 126–136, 2014.

[121] L. Danielyan, R. Klein, L. R. Hanson et al., “Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease,” *Rejuvenation Research*, vol. 13, no. 2-3, pp. 195–201, 2010.

[122] S. Indumathy, S. Kavimani, and K. V. Raman, “Role of angiotensin antagonists in memory enhancement,” *International Journal of Pharma and Bio Sciences*, vol. 1, no. 3, pp. 1–4, 2010.

[123] T. N. Grammatopoulos, S. M. Jones, F. A. Ahmadi et al., “Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra,” *Molecular Neurodegeneration*, vol. 2, no. 1, pp. 1–17, 2007.

[124] C. R. A. F. Diniz, P. C. Casarotto, S. M. Fred, C. Biojone, E. Castrén, and S. R. L. Joca, “Antidepressant-like effect of losartan involves TRKB transactivation from angiotensin type 1 receptor,” *Molecular Neurodegeneration*, vol. 135, pp. 163–171, 2018.

[125] M. S. Ivanova and R. E. Tashhev, “Intrahippocampal administration of losartan improves learning and memory in rats with model of depression,” *Bulgarian Chemical Communications*, vol. 49, pp. 169–174, 2017.

[126] S. Hong, H. JianCheng, W. JiaWen et al., “Losartan inhibits development of spontaneous recurrent seizures by preventing astrocyte activation and attenuating blood-brain barrier permeability following pilocarpine-induced status epilepticus,” *Brain Research Bulletin*, vol. 149, pp. 251–259, 2019.

[127] D. Atanasova, J. Tchekalova, N. Ivanova et al., “Losartan suppresses the kainate-induced changes of angiotensin AT1 receptor expression in a model of comorbid hypertension and epilepsy,” *Life Sciences*, vol. 193, pp. 40–46, 2018.

[128] J. D. Tchekalova, N. M. Ivanova, D. M. Pechlivanova et al., “Antiepileptogenic and neuroprotective effects of losartan in kainate model of temporal lobe epilepsy,” *Pharmacology Biochemistry and Behavior*, vol. 127, pp. 27–36, 2014.

[129] H. Sun, H. Q. Wu, X. Yu et al., “Angiotensin II and its receptor in activated microglia enhanced neuronal loss and cognitive impairment following pilocarpine-induced status epilepticus,” *Molecular and Cellular Neuroscience*, vol. 65, pp. 58–67, 2015.
G. Ping, Z. Zhao, U. I. Tuor, and P. Barber, "Angiotensin II type 1 receptor blocker losartan attenuates locomotor, anxiety-like behavior, and passive avoidance learning deficits in a sub-chronic stress model," *Iranian Journal of Basic Medical Sciences*, vol. 21, no. 8, pp. 856–862, 2018.

X. Gong, H. Hu, Y. Qiao et al., "The involvement of renin-angiotensin system in lipopolysaccharide-induced behavioral changes, neuroinflammation, and disturbed insulin signaling," *Frontiers in Pharmacology*, vol. 10, p. 318, 2019.

K. Genaro, D. Fabris, H. A. Fachim, and W. A. Prado, "Angiotensin AT1 receptors modulate the anxiogenic effects of angiotensin (5–8) injected into the rat ventrolateral periaqueductal gray," *Peptides*, vol. 96, pp. 8–14, 2017.

J. Xiong, Y. Gao, X. Li et al., "Losartan treatment could improve the outcome of TBI mice," *Frontiers in Neurology*, vol. 11, p. 992, 2020.

P. W. Pires, E. A. Ko, H. A. T. Pritchard, M. Rudokas, E. Hamel, K. Genaro, D. Fabris, H. A. Fachim, and W. A. Prado, "Angiotensin AT1 receptors protect the blood–brain barrier and improve the outcome of TBI mice," *Frontiers in Neurology*, vol. 12, pp. 36–40, 2020.

P. G. Keoh, P. S. Blair, B. Howden et al., "The rationale and design of the reducing pathology in Alzheimer’s disease through Angiotensin TaRgeting (RADAR) trial," *Journal of Alzheimer’s Disease*, vol. 61, no. 2, pp. 803–814, 2018.

Z. Zhao, U. I. Tuor, and P. Barber, "Chronic treatment with losartan and cerebral ischemic tolerance," *Journal of Experimental Stroke & Translational Medicine*, vol. 2, no. 2, pp. 32–40, 2009.

K. V. Anil Kumar, S. Nagwar, R. Thyloor, and S. Satyanarayana, "Anti-stress and nootropic activity of drugs affecting the renin-angiotensin system in rats based on indirect biochemical evidence," *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 16, no. 4, pp. 801–812, 2015.

G. Ping, W. Qian, G. Song, and S. Zhaochun, "Valsartan reverses depressive/anxiety-like behavior and induces hippocampal neurogenesis and expression of BDNF protein in unpredictable chronic mild stress mice," *Pharmacology Biochemistry and Behavior*, vol. 124, pp. 5–12, 2014.

L. J. Trigiani, J. Royea, M. Lacalle-Aurioles, X.-K. Tong, and E. Hamel, "Pleiotropic benefits of the angiotensin receptor blocker candesartan in a mouse model of Alzheimer disease," *Hypertension*, vol. 72, no. 5, pp. 1217–1226, 2018.

R. Goel, S. A. Bhat, K. Hanif, C. Nath, and R. Shukla, "Perindopril attenuates lipopolysaccharide-induced amyloidogenesis and memory impairment by suppression of oxidative stress and RAGE activation," *ACS Chemical Neuroscience*, vol. 7, no. 2, pp. 206–217, 2016.

B. Mertens, M. Varcin, Y. Michotte, and S. Sarre, "The neuroprotective action of candesartan is related to interference with the early stages of 6-hydroxydopamine-induced dopaminergic cell death," *European Journal of Neuroscience*, vol. 34, no. 7, pp. 1141–1148, 2011.

L. Wu, Y.-Y. Tian, J.-P. Shi et al., "Inhibition of endoplasmic reticulum stress is involved in the neuroprotective effects of candesartan cilexitil in the rotenone rat model of Parkinson’s disease," *Neuroscience Letters*, vol. 548, pp. 50–55, 2013.

J. J. Braszko, D. Wincewicz, and P. Jakubów, "Candesartan prevents impairment of recall caused by repeated stress in rats," *Psychopharmacology*, vol. 225, no. 2, pp. 421–428, 2013.

H. Yamakawa, M. Jezova, H. Ando, and J. M. Saavedra, "Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition," *Journal of Cerebral Blood Flow & Metabolism*, vol. 23, no. 3, pp. 371–380, 2003.

H. A. Ahmed, T. Israth, B. Pillai et al., "RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial," *Journal of Neuroinflammation*, vol. 15, no. 1, pp. 1–16, 2018.

T. Israth, B. Pillai, S. Soliman et al., "Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats," *Molecular Neurobiology*, vol. 51, no. 3, pp. 1542–1553, 2015.

J. Benicky, E. Sánchez-Lemus, M. Honda et al., "Angiotensin II AT1 Receptor Blockade Ameliorates Brain Inflammation," *Neuropsychopharmacology*, vol. 36, no. 4, pp. 857–870, 2011.

I. Hajjar, M. Okafor, D. McDaniel et al., "Effects of candesartan vs lisinopril on neurocognitive function in older adults with executive mild cognitive impairment: a randomized clinical trial," *JAMA Network Open*, vol. 3, no. 8, article e2012252, 2020.

B. K. Saxby, F. Harrington, K. A. Wenues, I. G. McKeith, and G. A. Ford, "Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial," *Neurology*, vol. 70, 19 Part 2, pp. 1858–1866, 2008.

H. Litsell, L. Hansson, I. Skoog et al., "The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial," *Journal of Hypertension*, vol. 21, no. 5, pp. 875–886, 2003.

S. Takeda, N. Sato, D. Takeuchi et al., "Angiotensin receptor blocker prevented β-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling," *Hypertension*, vol. 54, no. 6, pp. 1345–1352, 2009.

N. Pelisch, N. Hosomi, M. Ueno et al., "Blockade of AT1 receptors protects the blood–brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats," *American Journal of Hypertension*, vol. 24, no. 3, pp. 362–368, 2011.

I. Zakrocka, K. M. Targowska-Duda, A. Wnorowski, T. Kocki, K. Jóźwiak, and W. A. Turski, "Angiotensin II type 1 receptor blockers inhibit KAT II activity in the brain—in its possible clinical applications," *Neurotoxicity Research*, vol. 32, no. 4, pp. 639–648, 2017.

M. Ayyub, A. Najmi, and M. Akhtar, "Protective effect of irbesartan an angiotensin (AT1) receptor antagonist in unpredictable chronic mild stress induced depression in mice," *Drug Research*, vol. 67, no. 1, pp. 59–64, 2017.

M. Wiesmann, M. Roelofs, R. van der Lugt, A. Heerschap, M. Ayyub, A. Najmi, and M. Akhtar, "Neuroprotection of AT1 receptor antagonists in a model of brain ischemia reperfusion injury," *Molecular Neurobiology*, vol. 51, no. 3, pp. 1688–1699, 2014.

M. Ayyub, A. Najmi, and M. Akhtar, "Protective effect of irbesartan an angiotensin (AT1) receptor antagonist in unpredictable chronic mild stress induced depression in mice," *Drug Research*, vol. 67, no. 1, pp. 59–64, 2017.

G. A. Radaideh, Choueiry, Eid et al., "Eprosartan-based hytension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the
P. M. Rist, J. Chalmers, H. Arima et al., “Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study,” *Journal of Hypertension*, vol. 26, no. 8, pp. 1642–1650, 2008.

R. Kurosaki, Y. Muramatsu, H. Kato et al., “Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice,” *European Neuropsychopharmacology*, vol. 15, no. 1, pp. 57–67, 2005.

R. Kurosaki, Y. Muramatsu, Y. Imai, H. Kato, and T. Araki, “Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice,” *Neurological Research*, vol. 26, no. 6, pp. 644–657, 2004.

K. Yamada, T. Horita, M. Takayama et al., “Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypoperfusion rats,” *Brain Research*, vol. 1421, pp. 110–120, 2011.

M. R. A.-A. Ali, A. M. H. Abo-Youssef, B. A. S. Messihah, and M. M. Khattab, “Tempol and perindopril protect against lipopolysaccharide-induced cognition impairment and amyloidogenesis by modulating brain-derived neurotrophic factor, neuroinflammation and oxido-nitrosative stress,” *Naunyn-Schmiedeberg’s Archives of Pharmacology*, vol. 389, no. 6, pp. 637–656, 2016.

P. M. Rist, J. Chalmers, H. Arima et al., “Baseline cognitive function, recurrent stroke, and risk of dementia in patients with stroke,” *Stroke*, vol. 44, no. 7, pp. 1790–1795, 2013.

N. Chapman, R. Huxley, C. Anderson et al., “Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial,” *Stroke*, vol. 35, no. 1, pp. 116–121, 2004.

C. Tzourio, C. Anderson, and PROGRESS Management Committee, “Blood pressure reduction and risk of dementia in patients with stroke: rationale of the dementia assessment in PROGRESS (Perindopril Protection Against Recurrent Stroke Study). PROGRESS Management Committee,” *Journal of Hypertension. Supplement: Official Journal of the International Society of Hypertension*, vol. 18, no. 1, pp. S21–S24, 2000.

T. Ohru, N. Tomita, T. Sato-Nakagawa et al., “Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression,” *Neurology*, vol. 63, no. 7, pp. 1324–1325, 2004.

W. J. Louis, A. G. Mander, M. Dawson, C. O’Callaghan, and E. L. Conway, “Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly,” *Journal of Hypertension*, vol. 17, Supplement, pp. 1813–1819, 1999.

S. D. Hutcheon, N. D. Gillespie, I. K. Crombie, A. D. Struthers, and M. McMurdie, “Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial,” *Heart*, vol. 88, no. 4, pp. 373–377, 2002.

K. Asraf, N. Torika, R. N. Apte, and S. Fleisher-Berkovich, “Microglial activation is modulated by captopril: in vitro and in vivo studies,” *Frontiers in Cellular Neuroscience*, vol. 12, p. 116, 2018.

S. AbdAlla, A. Langer, X. Fu, and U. Quitterer, “ACE inhibition with captopril retards the development of signs of neurodegeneration in an animal model of Alzheimer’s disease,” *International Journal of Molecular Sciences*, vol. 14, no. 8, pp. 16917–16942, 2013.

A. Muñoz, P. Rey, M. J. Guerra, E. Mendez-Alvarez, R. Soto-Otero, and J. L. Labandeira-Garcia, “Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of Parkinsonism,” *Neuropharmacology*, vol. 51, no. 1, pp. 112–120, 2006.

Y. Tastemur, E. Gunus, M. Ergul et al., “Positive effects of angiotensin-converting enzyme (ACE) inhibitor, captopril, on pentyleneetrazole-induced epileptic seizures in mice,” *Tropical Journal of Pharmaceutical Research*, vol. 19, no. 3, pp. 637–643, 2020.

H. Luo, P.-F. Wu, Y. Cao et al., “Angiotensin-converting enzyme inhibitor rapidly ameliorates depressive-type behaviors via bradykinin-dependent activation of mammalian target of rapamycin complex 1,” *Biological Psychiatry*, vol. 88, no. 5, pp. 415–425, 2020.

B. Singh, B. Sharma, A. S. Jaggi, and N. Singh, “Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property,” *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 14, no. 2, pp. 124–136, 2013.

K. S. Thakur, A. Prakash, R. Bisht, and P. K. Bansal, “Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat,” *Journal of the Renin-Angiotensin-Aldosterone System*, vol. 16, no. 4, pp. 917–929, 2015.

A. Hariharan, S. Shetty, T. Shirole, and A. G. Jagtap, “Potential of protease inhibitor in 3-nitropionic acid induced Huntington’s disease like symptoms: mitochondrial dysfunction and neurodegeneration,” *Neurotoxicology*, vol. 45, pp. 139–148, 2014.

E. Uzar, A. Acar, O. Evliyaoğlu et al., “The anti-oxidant and anti-apoptotic effects of nebulovil and zofenopril in a model of cerebral ischemia/reperfusion in rats,” *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 36, no. 1, pp. 22–28, 2012.

G. de Sarro, E. D. D. Paola, S. Gratteri et al., “Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice,” *Pharmacological Research*, vol. 65, no. 3, pp. 285–296, 2012.

D. Deb, K. L. Bairy, V. Nayak, and M. Rao, “Comparative effect of Lisinopril and Fosinopril in mitigating learning and memory deficit in scopolamine-induced amnesic rats,” *Advances in Pharmacological Sciences*, vol. 2015, Article ID 521718, 11 pages, 2015.

T. C. Lee, D. Greene-Schloesser, V. Payne et al., “Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment,” *Radiation Research*, vol. 178, no. 1, pp. 46–56, 2012.

E. Lonn, R. Roccaforte, Q. Yi et al., “Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial,” *Journal of the American College of Cardiology*, vol. 39, pp. 290–291, 2002.

H. Panahpour, N. A. Terpolilli, D. Schaffert, C. Culmsee, and N. Plesnila, “Central application of aliskiren, a renin inhibitor, improves outcome after experimental stroke independent of..."
of its blood pressure lowering effect,” *Frontiers in Neurology*, vol. 10, p. 942, 2019.

[183] K. Łukawski, G. Raszewski, and S. J. Czuczwar, “Effect of aliskiren on the anticonvulsant activity of antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice,” *Epilepsy Research*, vol. 167, p. 106435, 2020.

[184] M. Smith, T. M. Woodruff, B. D. Wyse, A. Muralidharan, and T. Walther, “A small molecule angiotensin II type 2 receptor (AT2R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia,” *Pain Medicine (Malden, Mass.)*, vol. 14, no. 10, pp. 1557–1568, 2013.

[185] L. Pulakat and C. Sumners, “Angiotensin type 2 receptors: painful, or not?,” *Frontiers in Pharmacology*, vol. 11, p. 2180, 2020.